Towards the Grade of Recommendations, Assessment, Development and Evaluation system: Methods and results of budesonide/formoterol maintenance and reliever therapy research

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 4, 2011, Pages 361-374

  Braido, Fulvio ^a   Baiardini, Ilaria ^a   Compalati, Enrico ^a   Bordo, Alberto ^a   Canonica, Giorgio W ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

asthma; control; exacerbations

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; SALBUTAMOL; TERBUTALINE;

ABSENTEEISM; AROUSAL; ASTHMA; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GRADE OF RECOMMENDATIONS, ASSESSMENT, DEVELOPMENT AND EVALUATION SYSTEM; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; METHODOLOGY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTPATIENT CARE; PATIENT SATISFACTION; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BIAS (EPIDEMIOLOGY); BUDESONIDE; CHILD; COSTS AND COST ANALYSIS; DATA COLLECTION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; MULTICENTER STUDIES AS TOPIC; PATIENT SATISFACTION; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 79960837948     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283489c0e     Document Type: Review

References (37)

1. Greening AP, Ind PW, Northfield M, Shaw G, Added salmeterol versus higherdose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid, Allen & Hanburys Limited UK Study Group, Lancet 1994; 344:219-224. (Pubitemid 24229008)
2. Pauwels RA, Lö fdahl CG, Postma DS, et al, Effect of inhaled formoterol and budesonide on exacerbations of asthma, Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group, N Engl J Med 1997; 337:1405-1411.
3. Global strategy for asthma management and prevention 2009 , www.ginasthma.org [Accessed 15 March 2011].
4. Bateman ED, Boushey HA, Bousquet J, et al., GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study, Am J Respir Crit Care Med 2004; 170:836-844.
5. O'Byrne PM, Naya IP, Kallen A, et al, Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control, Chest 2008; 134:1192-1199.
6. Bateman ED, Bousquet J, Keech ML, et al, The correlation between asthma control and health status: the GOAL study, Eur Respir J 2007; 29:56-62.
7. Juniper EF, Svensson K,O'Byrne PM, et al, Asthma quality of life during 1 year of treatment with budesonide with or without formoterol, Eur Respir J 1999; 14:1038-1043.
8. Lasserson TJ, Cates CJ, Ferrara G, Casali L, Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children, Cochrane Database Syst Rev 2008:CD004106.
9. Palmqvist M, Arvidsson P, Beckman O, et al, Onset of bronchodilation of budesonide/formoterol vs, salmeterol/fluticasone in single inhalers, Pulm Pharmacol Ther 2001; 14:29-34. (Pubitemid 32158294)
10. van der Woude HJ, Boorsma M, Bergqvist PB, et al, Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction, Pulm Pharmacol Ther 2004; 17:89-95. (Pubitemid 38175340)
11. Hampel FC, Martin P, Mezzanotte WS, Early bronchodilatory effects of budesonide/ formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids, J Asthma 2008; 45:265-272. (Pubitemid 351630914)
12. O'Connor RD, Patrick DL, Parasuraman B, et al, Patient satisfaction during treatment with adjustable-dose budesonide/formoterol pressurized metereddose inhaler (BUD/FM pMDI), fixed-dose BUD/FM pMDI, and fixed-dose fluticasone/salmeterol dry powder inhaler (FP/SM DPI) [poster], American Thoracic Society, 16-21 May 2008; Toronto.
13. Peters SP, Jones CA, Haselkorn T, et al, Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol 2007; 119:1454-1461. (Pubitemid 46863372)
14. Cazzoletti L, Marcon A, Janson C, et al., Therapy and Health Economics Group of the European Community Respiratory Health Survey, Asthma control in Europe: a real-world evaluation based on an international population-based study, J Allergy Clin Immunol 2007; 120:1360-1367. (Pubitemid 350225685)
15. Partridge MR, van der Molen T, Myrseth SE, Busse WW, Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study, BMC Pulm Med 2006; 6:13.
16. Foresi A, Morelli MC, Catena E, Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group, Chest 2000; 117:440-446. (Pubitemid 30111596)
17. Guyatt GH, Oxman AD, Vist G, Kunz R, et al., for the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926. (Pubitemid 351632017)
18. Scicchitano R, Aalbers R, Ukena D, et al, Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma, Curr Med Res Opin 2004; 20:1403-1418. (Pubitemid 39361344)
19. O'Byrne PM, Bisgaard H, Godard PP, et al, Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma, Am J Respir Crit Care Med 2005; 171:129-136. (Pubitemid 40105411)
20. Vogelmeier C, D'Urzo A, Pauwels R, et al, Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26:819-828. (Pubitemid 41632038)
21. Rabe KF, Pizzichini E, Stä llberg B, et al, Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial, Chest 2006; 129:246-256. (Pubitemid 43289841)
22. Rabe KF, Atienza T, Magyar P, et al, Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study, Lancet 2006; 368:744-753. (Pubitemid 44279053)
23. Lundborg M, Wille S, Bjermer L, et al, Maintenance plus reliever budesonide/ formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study, Curr Med Res Opin 2006; 22:809-821. (Pubitemid 43875550)
24. Bisgaard H, Le Roux P, Bjämer D, et al, Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma, Chest 2006; 130:1733-1743. (Pubitemid 46033427)
25. Bousquet J, Boulet LP, Peters MJ, et al, Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs, high-dose salmeterol/ fluticasone. Respir Med 2007; 101:2437-2446. (Pubitemid 350010579)
26. Kuna P, Peters MJ, Manjra AI, et al, Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations, Int J Clin Pract 2007; 61:725-736. (Pubitemid 46587876)
27. Sears MR, Boulet LP, Laviolette M, et al, Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma, Eur Respir J 2008; 31:982-989.
28. Stä llberg B, Ekström T, Neij F, et al., SHARE trial group, A real-life costeffectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma, Respir Med 2008; 102:1360-1370.
29. Pavord ID, Jeffery PK, Qiu Y, et al, Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol, J Allergy Clin Immunol 2009; 123:1083-1089; 1089.e1-7.
30. Louis R, Joos G, Michils A, Vandenhoven G, A comparison of budesonide/formoterol maintenance and reliever therapy vs, conventional best practice in asthma management, Int J Clin Pract 2009; 63:1479-1488.
31. Agarwal R, Khan A, Aggarwal AN, Gupta D, Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis, Monaldi Arch Chest Dis 2009; 71:161-169.
32. Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF, Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma, Pharmacoeconomics 2006; 24:695-708. (Pubitemid 43998822)
33. Price D, Wirén A, Kuna P, Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy, Allergy 2007; 62:1189-1198. (Pubitemid 47374022)
34. Patrick DL, Burke LB, Powers JH, et al, Patient-reported outcomes to support medical product labeling claims: FDA perspective, Value Health 2007; 10:S125-S137. (Pubitemid 350098929)
35. Baiardini I, Bousquet PJ, Brzoza Z, et al, Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA[2)LEN taskforce position paper, Allergy 2010; 65:290-295.
36. Braido F, Bousquet PJ, Brzoza Z, et al, Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper, Allergy 2010; 65:959-968.
37. Chapman KR, Barnes NC, Greening AP, et al, Single Maintenance and Reliever Therapy (SMART) of asthma: a critical appraisal, Thorax 2010; 65:747-752.